CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD
Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 195 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CORT a very profitable company, without any liquidiy or solvency issues. CORT is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, CORT could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
In the past year CORT had a positive cash flow from operations.
Each year in the past 5 years CORT has been profitable.
In the past 5 years CORT always reported a positive cash flow from operatings.
1.2 Ratios
CORT's Return On Assets of 15.83% is amongst the best of the industry. CORT outperforms 97.44% of its industry peers.
With an excellent Return On Equity value of 19.61%, CORT belongs to the best of the industry, outperforming 92.82% of the companies in the same industry.
CORT has a Return On Invested Capital of 13.61%. This is amongst the best in the industry. CORT outperforms 90.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CORT is above the industry average of 14.87%.
The last Return On Invested Capital (13.61%) for CORT is well below the 3 year average (17.94%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.83% | ||
| ROE | 19.61% | ||
| ROIC | 13.61% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT's Profit Margin of 19.55% is amongst the best of the industry. CORT outperforms 93.33% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
The Operating Margin of CORT (16.17%) is better than 85.13% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 98.43%, CORT belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
CORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.17% | ||
| PM (TTM) | 19.55% | ||
| GM | 98.43% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CORT is creating value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 30.67 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT has a better Altman-Z score (30.67) than 94.36% of its industry peers.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 30.67 |
ROIC/WACC1.38
WACC9.83%
2.3 Liquidity
A Current Ratio of 3.07 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio (3.07) which is comparable to the rest of the industry.
CORT has a Quick Ratio of 2.96. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT's Quick ratio of 2.96 is in line compared to the rest of the industry. CORT outperforms 56.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.43% over the past year.
CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.71% yearly.
The Revenue has grown by 30.93% in the past year. This is a very strong growth!
The Revenue has been growing by 17.11% on average over the past years. This is quite good.
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 56.00% yearly.
CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.41% yearly.
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue Next Year29.78%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 61.97, CORT can be considered very expensive at the moment.
78.97% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of CORT to the average of the S&P500 Index (27.47), we can say CORT is valued expensively.
With a Price/Forward Earnings ratio of 26.49, CORT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CORT is valued a bit cheaper than 70.77% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.91. CORT is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.97 | ||
| Fwd PE | 26.49 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 76.41% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than 79.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.02 | ||
| EV/EBITDA | 62.88 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CORT does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CORT may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 70.13% in the coming years.
PEG (NY)4.66
PEG (5Y)6.38
EPS Next 2Y47.92%
EPS Next 3Y70.13%
5. Dividend
5.1 Amount
No dividends for CORT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
71.88
-0.13 (-0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners79.51%
Inst Owner Change0%
Ins Owners6.55%
Ins Owner Change0.39%
Market Cap7.62B
Analysts82
Price Target141.01 (96.17%)
Short Float %13.49%
Short Ratio8.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.62%
Min EPS beat(2)-40.2%
Max EPS beat(2)16.96%
EPS beat(4)3
Avg EPS beat(4)13.93%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)7
Avg EPS beat(8)20.33%
EPS beat(12)9
Avg EPS beat(12)10.46%
EPS beat(16)12
Avg EPS beat(16)11.02%
Revenue beat(2)0
Avg Revenue beat(2)-11.81%
Min Revenue beat(2)-13.38%
Max Revenue beat(2)-10.25%
Revenue beat(4)2
Avg Revenue beat(4)-4.03%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)-0.63%
Revenue beat(12)7
Avg Revenue beat(12)-1.42%
Revenue beat(16)8
Avg Revenue beat(16)-1.72%
PT rev (1m)-0.9%
PT rev (3m)-2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.27%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.98%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 61.97 | ||
| Fwd PE | 26.49 | ||
| P/S | 11.12 | ||
| P/FCF | 43.02 | ||
| P/OCF | 42.48 | ||
| P/B | 11.16 | ||
| P/tB | 11.16 | ||
| EV/EBITDA | 62.88 |
EPS(TTM)1.16
EY1.61%
EPS(NY)2.71
Fwd EY3.77%
FCF(TTM)1.67
FCFY2.32%
OCF(TTM)1.69
OCFY2.35%
SpS6.46
BVpS6.44
TBVpS6.44
PEG (NY)4.66
PEG (5Y)6.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.83% | ||
| ROE | 19.61% | ||
| ROCE | 15.76% | ||
| ROIC | 13.61% | ||
| ROICexc | 25.27% | ||
| ROICexgc | 25.27% | ||
| OM | 16.17% | ||
| PM (TTM) | 19.55% | ||
| GM | 98.43% | ||
| FCFM | 25.85% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 159.44% | ||
| Profit Quality | 132.22% | ||
| Current Ratio | 3.07 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | 30.67 |
F-Score6
WACC9.83%
ROIC/WACC1.38
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y56%
Revenue 1Y (TTM)30.93%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
Revenue Next Year29.78%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y30.41%
EBIT growth 1Y-9.1%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year20.41%
EBIT Next 3Y47.8%
EBIT Next 5Y19.15%
FCF growth 1Y60.04%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y61.51%
OCF growth 3Y5.66%
OCF growth 5Y7.79%